Humacyte Presents Long-Term Data on Symvess at VESS Annual Meeting
Humacyte announced the presentation of long-term data assessing the durability of Symvess in extremity arterial trauma patients at the Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society, VESS, in Olympic Valley, CA. The presentation, titled "Long-Term Outcomes of the Acellular Tissue Engineered Vessel in Extremity Arterial Trauma Repair: Results from the V005 Trial." In the V005 trial, Symvess maintained long-term structural integrity, exhibited low infection rates, and supported high rates of limb salvage in patients who were followed for up to 36 months. Among those treated in the V005 Phase 2/3 study were 54 patients who underwent extremity vascular repair with Symvess for whom treatment with autologous vein, the standard of care, was not feasible. Within this patient population, once early complications from the traumatic injuries resolved, the rates of conduit infection, limb salvage, and patient survival plateaued and remained relatively constant through the three years of follow-up. Symvess maintained an infection-free rate of 92.9% from months 3-36, with no infections after day 37 and only three conduit infections overall. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months, despite a severely injured trauma cohort.
Trade with 70% Backtested Accuracy
Analyst Views on HUMA
About HUMA
About the author
Eligibility Verification for Huma Open Season 3 Airdrop
- Eligibility Check Announcement: Huma Finance has announced that the eligibility check for the third-quarter air drop is now open.
- Air Drop Details: The announcement indicates that participants can now verify their eligibility for the upcoming air drop event.
Humacyte Secures Congressional Funding for Bioengineered Vessels
- Legislative Support: The U.S. Congress passed the FY 2026 DoD Appropriations Act, providing funding for Humacyte's human-derived bioengineered vessel, Symvess, which is expected to enhance the company's market share in treating traumatic vascular injuries.
- Integration Requirement: The bill mandates the DoD to integrate FDA-approved breakthrough vascular repair technologies, ensuring the availability of biologically active vascular conduits when autologous vein harvesting is not feasible, thereby increasing demand for Humacyte's products.
- FDA Approval: In December 2024, the FDA approved Symvess as an implantable vascular conduit for various arterial injury scenarios, marking a significant technological breakthrough for Humacyte and strengthening its competitive position in the medical market.
- CEO Remarks: Humacyte's CEO Laura Niklason stated that this historic federal investment will ensure soldiers have access to cutting-edge treatments, further enhancing the company's strategic position in the defense healthcare sector.
Humacyte Secures DOD Funding for Bioengineered Blood Vessels
- Funding Support: Humacyte Inc. announced that the FY2026 U.S. Department of Defense Appropriations Act includes funding for the procurement of bioengineered blood vessels, aimed at evaluating and integrating biologic vascular repair technologies for warfighters with traumatic vascular injuries.
- Product Uniqueness: Humacyte's Symvess is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA), which enhances its competitive edge in the medical device market and positions the company favorably against competitors.
- Stock Price Reaction: Humacyte shares rose nearly 12% in Monday's pre-market trading, reflecting a positive market response to the newly secured funding and product potential, which may attract more investor interest.
- Market Sentiment: Despite the stock price increase, retail sentiment on Stocktwits around Humacyte trended in the 'bearish' territory, indicating a divergence in market perception regarding the company's future performance, which could impact its short-term stock trajectory.
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Benchmark Reaffirms Buy Rating on Humacyte, Adjusts Price Target to $11
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
Eligibility Verification for Huma Open Season 3 Airdrop
- Eligibility Check Announcement: Huma Finance has announced that the eligibility check for the third-quarter air drop is now open.
- Air Drop Details: The announcement indicates that participants can now verify their eligibility for the upcoming air drop event.
Humacyte Secures Congressional Funding for Bioengineered Vessels
- Legislative Support: The U.S. Congress passed the FY 2026 DoD Appropriations Act, providing funding for Humacyte's human-derived bioengineered vessel, Symvess, which is expected to enhance the company's market share in treating traumatic vascular injuries.
- Integration Requirement: The bill mandates the DoD to integrate FDA-approved breakthrough vascular repair technologies, ensuring the availability of biologically active vascular conduits when autologous vein harvesting is not feasible, thereby increasing demand for Humacyte's products.
- FDA Approval: In December 2024, the FDA approved Symvess as an implantable vascular conduit for various arterial injury scenarios, marking a significant technological breakthrough for Humacyte and strengthening its competitive position in the medical market.
- CEO Remarks: Humacyte's CEO Laura Niklason stated that this historic federal investment will ensure soldiers have access to cutting-edge treatments, further enhancing the company's strategic position in the defense healthcare sector.
Humacyte Secures DOD Funding for Bioengineered Blood Vessels
- Funding Support: Humacyte Inc. announced that the FY2026 U.S. Department of Defense Appropriations Act includes funding for the procurement of bioengineered blood vessels, aimed at evaluating and integrating biologic vascular repair technologies for warfighters with traumatic vascular injuries.
- Product Uniqueness: Humacyte's Symvess is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA), which enhances its competitive edge in the medical device market and positions the company favorably against competitors.
- Stock Price Reaction: Humacyte shares rose nearly 12% in Monday's pre-market trading, reflecting a positive market response to the newly secured funding and product potential, which may attract more investor interest.
- Market Sentiment: Despite the stock price increase, retail sentiment on Stocktwits around Humacyte trended in the 'bearish' territory, indicating a divergence in market perception regarding the company's future performance, which could impact its short-term stock trajectory.
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Benchmark Reaffirms Buy Rating on Humacyte, Adjusts Price Target to $11
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
